Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine effects on brain network topology in Alzheimer's disease
jRCTs031180337Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of galantamine in Alzheimer's disease (AD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Short-term effects of galantamine on brain network topology. Started Feb 2017; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCTs031180337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180337.